Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kōtoku
Clinical trial register · Japan

Clinical Trials in Kōtoku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca56 Daiichi Sankyo21 EMD Serono Research & Development Institute, Inc.5 Incyte Corporation3 Eli Lilly and Company3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kōtoku

99 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
Sun Pharma Japan Limited
Phase 3
78
Asahikawa, Bunkyō City, Ebina, Hamamatsu, Ishikawa, Kitakyushu, Kōtoku, Kurashiki
2026-06-19
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki
2026-05-20
Recruiting
Genmab
Phase 2
160
Kashiwa, Yokohama, Suita, Kōtoku
2026-05-11
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Nagoya, Fukuoka, Yokohama, Sakai-shi, Kitaadachi-gun, Chūōku, Kōtoku, Osaka
2026-05-06
Recruiting
Incyte Corporation
Phase 3
588
Akashi, HYGO, Fukuoka Fukuoka, Kahoku-gun, Kitaadachi-gun, Kōtoku, Mitaka-shi, Osaka, Sapporo Hokkaido
2026-04-09
Recruiting
AstraZeneca
Phase 3
2,130
Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi
2026-02-03
Recruiting
AstraZeneca
Phase 3
1,100
Akashi-shi, Chūōku, Hidaka-shi, Kashiwa, Kobe, Kōtoku, Kurume-shi, Nagoya
2025-12-29
Recruiting
Incyte Corporation
Phase 3
466
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama
2025-12-09
Recruiting
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
Daiichi Sankyo
Phase 1
60
Kashiwa-shi, Kobe, Kōtoku, Sakura-shi
2025-12-03
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Himeji, Kōtoku, Kyoto, Nagaizumi-cho,Sunto-gun
2025-11-28
Recruiting
Incyte Corporation
Phase 2
160
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Sapporo, Sunto-gun
2025-11-12
Recruiting
AstraZeneca
Phase 3
420
Akashi, Bunkyō City, Himeji-shi, Kōtoku, Kumamoto, Matsumoto-shi, Matsuyama, Meguro-ku
2025-11-11
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
Eli Lilly and Company
Phase 3
1,630
Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya
2025-10-22
Recruiting
Daiichi Sankyo
Phase 1
192
Kashiwa, Kōtoku
2025-10-02
Recruiting
AstraZeneca
Phase 1/2
283
Chūōku, Kashiwa, Kōtoku
2025-10-01
Recruiting
Daiichi Sankyo
Phase 3
710
Akashi-shi, Fukuoka, Fukushima, Hidaka-shi, Kōtoku, Kurume-shi, Niigata, Okayama
2025-09-30
Recruiting
Daiichi Sankyo
Phase 2/3
630
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto
2025-09-26
Recruiting
AstraZeneca
Phase 1/2
91
Bunkyō City, Kōtoku
2025-09-24
Recruiting
AstraZeneca
Phase 3
800
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku
2025-08-01
Recruiting
AstraZeneca
Phase 2
100
Chūōku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osaka
2025-07-17
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Chūōku, Kashiwa, Kōtoku
2025-04-29
Recruiting
Daiichi Sankyo
Phase 3
510
Chūōku, Hiroshima, Kashiwa, Kita-gun, Kobe, Kōtoku, Matsuyama, Nagoya
2025-03-27
Recruiting
AstraZeneca
Phase 3
600
Akashi-shi, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa, Kashiwa-shi, Kobe, Kōtoku
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
582
Akashi, Chūōku, Fukushima, Hidaka-Shi, Kōtoku, Kurume-shi, Nagoya, Niigata
2025-03-19
Recruiting
Daiichi Sankyo
Phase 3
726
Bunkyō City, Chūōku, Gifu, Hiroshima, Kashiwa-shi, Kitakyushu, Kochi, Kōtoku
2025-02-27
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Kōtoku, Matsuyama, Nagoya
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Chūōku, Kashihara-shi, Kōtoku, Kumamoto, Kurume-shi, Niigata, Osakasayama-shi, Sapporo
2025-01-29
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Kōtoku
2025-01-28
Active, closed
Daiichi Sankyo
Phase 2
335
Akashi, Chūōku, Fukuoka, Hidaka, Kashiwa, Kōtoku, Nagoya, Osaka
2025-01-06
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
2024-11-27
Active, closed
Daiichi Sankyo
Phase 1/2
137
Fukuoka, Kashiwa, Kōtoku, Nagoya, Sagamihara-shi
2024-10-30
Active, closed
AstraZeneca
Phase 3
768
Bunkyō City, Fukuoka, Hiroshima, Iruma-Gun, Iwakuni-shi, Kobe, Kōtoku, Kumamoto
2024-10-04
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Fukuoka, Kashiwa-shi, Kōtoku, Kumamoto
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2024-08-01
Recruiting
Daiichi Sankyo
Phase 1/2
123
Himeji-shi, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Nagaizumi-cho, Niigata, Okayama
2024-07-22
Recruiting
Daiichi Sankyo
Phase 3
540
Chūōku, Fukuoka, Hirakata-shi, Kashiwa, Kōtoku, Matsuyama, Nakatogari, Okayama
2024-05-21
Recruiting
AstraZeneca
Phase 3
582
Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo
2024-04-29
Active, closed
AstraZeneca
Phase 3
594
Fukuoka, Kashiwa, Kōtoku, Nagoya, Ogaki-shi, Osaka, Sunto-gun, Tokyo
2024-03-04
Recruiting
Daiichi Sankyo
Phase 2/3
860
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-cho
2024-02-27
Active, closed
Daiichi Sankyo
Phase 1
210
Chūōku, Fukuoka, Kashiwa, Kōtoku, Nagoya, Osaka, Ōsaka-sayama, Shizuoka
2024-02-22
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Bunkyō City, Kōtoku
2024-01-23
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Chūōku, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi
2023-12-13
Active, closed
AstraZeneca
Phase 3
760
Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Mitaka-shi, Nagoya, Osaka, Sendai
2023-12-04
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Fukuoka, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Okayama
2023-10-24
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsTRK-950·Ramucirumab·Paclitaxel
Toray Industries, Inc
Phase 2
146
Yokohama, Shinden, Nagaizumi-cho, Chūōku, Kashiwa, Kōtoku
2023-10-04
Recruiting
AstraZeneca
Phase 3
800
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama
2023-09-22
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Osaka, Ōsaka-sayama, Sapporo
2023-08-18
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Chūōku, Kashiwa, Kōtoku
2023-07-11
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Hidaka-shi, Kashiwa, Kōtoku, Sunto-gun, Tokyo
2023-06-05
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Chūōku, Kashiwa, Kōtoku
2022-12-21
Active, closed
AstraZeneca
Phase 3
594
Bunkyō City, Chūōku, Kōtoku, Kurashiki-shi, Kurume-shi, Matsuyama, Nagoya, Niigata
2022-09-15
Recruiting
AstraZeneca
Phase 2
454
Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
2022-09-06
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
Chūōku, Kashiwa-shi, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi, Sunto-gun, Yokohama
2022-08-04
Active, closed
Gilead Sciences
Phase 3
623
Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2022-07-20
Active, closed
Daiichi Sankyo
Phase 3
586
Akashi, Fukuoka, Hidaka, Hirakata, Iwakuni, Izumi, Kanazawa, Kōtoku
2022-07-08
Active, closed
AstraZeneca
Phase 3
644
Chūōku, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun, Kōtoku
2022-05-16
By invitation
AstraZeneca
Phase 3
214
Bunkyō City, Fukuoka, Kanazawa, Kōtoku, Nagoya, Okayama, Saga, Sunto-gun
2022-04-19
Active, closed
ARCAGY/ GINECO GROUP
Phase 3
260
Fukuoka, Fukushima, Kōtoku, Saitama
2022-04-15
Active, closed
Daiichi Sankyo
Phase 2
187
Chūōku, Kashiwa, Kōtoku, Nagaizumi-chō, Osaka, Ōsaka-sayama, Yokohama
2022-03-09
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Bunkyō City, Chiba, Fukuoka, Hidaka-shi, Hirosaki-shi, Itabashi-ku, Kashihara-shi, Kōtoku
2022-02-18
Active, closed
AstraZeneca
Phase 3
927
Chūōku, Hidaka-shi, Hiroshima, Kawasaki-shi, Kōtoku, Nagoya, Ota-shi, Shinjuku-ku
2021-10-25
Recruiting
AstraZeneca
Phase 1/2
460
Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
2021-10-18
Active, closed
HUYABIO International, LLC.
Phase 3
450
Fukuoka, Matsumoto, Niigata, Okayama, Chuo Ku, Osaka, Nagaizumi-cho, Kōtoku
2021-08-12
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
Daiichi Sankyo
Phase 3
490
Nagoya, Chūōku, Gifu, Kashiwa, Kobe, Kochi, Kōtoku, Matsuyama
2021-05-21
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
DrugSurovatamig
AstraZeneca
Phase 1
226
Chūōku, Kōtoku, Nagoya, Yamagata
2021-03-02
Active, closed
AstraZeneca
Phase 1
155
Kōtoku, Sunto-gun, Yokohama
2021-02-02
Active, closed
AstraZeneca
Phase 3
1,371
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Active, closed
Daiichi Sankyo
Phase 1
179
Chuo Ku, Kashiwa-shi, Fukuoka, Kōtoku, Matsuyama, Nakatogari, Saitama
2020-12-22
Active, closed
Daiichi Sankyo
Phase 3
605
Akashi, Chūōku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kōtoku
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Active, closed
Incyte Biosciences Japan GK
Phase 1/2
72
Aichi, Chiba, Fukui, Fukuoka, Hyōgo, Kanagawa, Kōtoku, Kumamoto-ken
2020-12-15
Active, closed
Daiichi Sankyo
Phase 3
1,600
Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku
2020-12-04
Active, closed
AstraZeneca
Phase 1/2
702
Chūōku, Kōtoku
2020-11-12
Active, closed
AstraZeneca
Phase 3
640
Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku
2020-10-19
Active, closed
Daiichi Sankyo
Phase 1
40
Chūōku, Kashiwa, Kōtoku
2020-10-09
Active, closed
Acerta Pharma BV
Phase 3
611
Chiba, Chūōku, Fukuoka, Itabashi-ku, Kahoku-gun, Kashiwa, Kobe, Kōtoku
2020-10-08
Active, closed
AstraZeneca
Phase 3
370
Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama
2020-10-02
Active, closed
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Bunkyō City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kōtoku, Kyoto, Niigata
2020-03-30
Active, closed
AstraZeneca
Phase 3
587
Bunkyō City, Fukuoka, Hidaka-shi, Himeji-shi, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Bunkyō City, Fukuoka, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku, Kumamoto
2019-06-25
Active, closed
AstraZeneca
Phase 2
247
Chūōku, Fukuoka, Kōtoku, Nagoya, Osaka, Wakayama
2019-06-25
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Chūōku, Habikino-shi, Kōtoku, Kurume-shi, Osaka, Sendai, Suita-shi
2019-03-22
Active, closed
AstraZeneca
Phase 3
1,407
Fukuoka, Kashiwa-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya
2019-01-04
Active, closed
AstraZeneca
Phase 3
1,063
Bunkyō City, Fukuoka, Hirosaki-shi, Hiroshima, Kanazawa, Kōtoku, Kumamoto, Miyazaki
2018-11-16
Active, closed
AstraZeneca
Phase 3
730
Bunkyō City, Chūōku, Fukuoka, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi, Nagoya
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,018
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku, Matsuyama
2018-05-14
Active, closed
AstraZeneca
Phase 3
1,324
Bunkyoku, Chiba, Fukuoka, Hiroshima, Iizuka, Kanazawa, Kōtoku, Kumamoto
2017-10-11
Active, closed
AstraZeneca
Phase 3
1,186
Bunkyō City, Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2017-06-01
Active, closed
AstraZeneca
Phase 3
987
Chūōku, Fukuoka, Fukushima, Himeji-shi, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi
2017-03-27
Rows per page Showing 1–99 of 99
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/k-toku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 99 of those studies with a site in Kōtoku.

How many clinical trials are recruiting in Kōtoku?

45 of the 99 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 53 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kōtoku), 99 studies
PhaseStudiesRecruitingShare
Phase 3602260.6%
Phase 1/214914.1%
Phase 212912.1%
Phase 110210.1%
Phase 2/3333%

Most active sponsors

Lead sponsors with the most studies (Kōtoku)
Lead sponsorStudiesRecruiting
AstraZeneca5622
Daiichi Sankyo2111
EMD Serono Research & Development Institute, Inc.51
Eli Lilly and Company33
Incyte Corporation33
Acerta Pharma BV10
ARCAGY/ GINECO GROUP10
Astellas Pharma Global Development, Inc.10
Bicara Therapeutics11
BioNTech SE11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.